Non-Hodgkin Lymphomas (NHLs) are a heterogeneous group of tumours with distinct treatment paradigms, but in all cases the goal of treatment is to maximize quality and duration of remission while minimizing therapy-related toxicity. Identification of persistent disease or relapse is most often the trigger to intensify or re-initiate anti-neoplastic therapy, respectively. In the current era of NHL treatment, this determination is mostly based on imaging and clinical evaluations, tools with imperfect sensitivity and specificity. The availability of minimal residual disease (MRD) monitoring could transform treatment paradigms by allowing intensification of treatment in at-risk patients or early intervention for impending relapse. Novel methods based on polymerase chain reaction and next-generation sequencing are now being studied in NHL with promising results. This review outlines the current status of the field in the use of MRD techniques for diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma. Specifically, we address their demonstrated and potential clinical utility in risk stratification, monitoring of remission status, and guiding interim and post-treatment escalation. Future applications of these techniques could identify novel markers of MRD, improve initial treatment selection, guide treatment escalation or de-escalation, and allow for real-time monitoring of patterns of clonal evolution, which together could redefine NHL treatment paradigms.
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Non-Hodgkin Lymphomas (NHLs) are a heterogeneous group of malignancies with distinct prognoses and therapeutic approaches (Zelenetz et al, 2010) . Decisions on treatment, while made on an individual basis, must always weigh the risk of therapy-related toxicity against the potential benefit in terms of survival, remission duration and quality of life. Despite the use of molecular risk stratification systems and advanced imaging during and after therapy, our ability to reliably prognosticate is still limited and, even in curable lymphoma subtypes, it remains impossible to definitively identify patients who are cured at the end of first-line therapy. Important and related challenges in the management of NHL continue to be the early identification of patients who are most likely to relapse after curative-intent therapy, and the identification of patients who are likely to relapse early after non-curative intent therapy. These individuals may be selected for treatment change, continuation or intensification, in an effort to maximize their progression-free (PFS) and overall survival (OS).
At present, positron emission tomography (PET) and computed tomography (CT) scanning are the principal tools to assess remission status, drive decisions on treatment alteration and identify relapse (Thompson et al, 2014; Huntington et al, 2015; Adams et al, 2016) . However they are associated with non-negligible radiation exposure, increasing the risk of secondary malignancy (Chien et al, 2015) . In addition, they are not sufficiently sensitive to reliably predict therapy failure or impending relapse (Pregno et al, 2012) . Molecular techniques that can detect and quantify minimal residual disease (MRD) have the potential to improve the treatment of NHL, as they are more sensitive than imaging in the measurement of residual disease and can do so without radiation exposure. MRD techniques have long been applied to haematological malignancies with a significant circulating component and abnormal immunophenotype, such as acute lymphoblastic leukaemia and chronic lymphocytic leukaemia (CLL) (Alix-Panabi eres & Pantel, 2016; Ossenkoppele & Schuurhuis, 2016; Paiva et al, 2016; Thompson & Wierda, 2016) . Only recently has the development of robust techniques, including next-generation sequencing (NGS), opened the door to similar research in NHL (Wu et al, 2012; Logan et al, 2014; Pieters et al, 2016) . Several techniques are now in development or testing that may be applicable across NHL histologies, and ultimately, these may dramatically alter treatment paradigms in lymphoma (Kurtz et al, 2015 Roschewski et al, 2015) . In this review, we briefly discuss the technical bases of some of those methods, and their early and potential uses in a few NHL subtypes. While some of the MRD techniques described here are potentially applicable to all NHL histologies, we will focus this review on the three diseases for which we have the most results to date: diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL).
Application of molecular diagnostics
Immunohistochemical (IHC) staining and multidetector flow cytometry (MFC) have been in widespread use in the evaluation of tissue from haematological malignancies since the 1980's, with significant benefits. They have allowed the identification of diagnostic and prognostic disease characteristics; have been used to guide initial treatment selection and ascertain remission status, and, in select circumstances, have been used to guide treatment intensification or the initiation of maintenance therapy (Landgren & Giralt, 2016; Ossenkoppele & Schuurhuis, 2016; Pieters et al, 2016; Thompson & Wierda, 2016) . While the usefulness of these methods is beyond debate, they have several notable limitations with respect to their use for MRD monitoring. Obtaining tissue for IHC staining in NHL patients most often requires invasive procedures. Furthermore, the expected shrinkage in tumours after treatment makes repeated biopsy more difficult and of lower yield. Therefore, IHC cannot be easily used as a method for interim monitoring or surveillance. MFC can circumvent some of those challenges by potentially allowing the detection of circulating tumour cells (CTCs) from peripheral blood, obviating the need for tissue biopsy (Cheminant et al, 2016) . To be clinically useful, MFC requires a pattern of cell surface markers unique to the malignancy at hand, and a high enough level of circulating disease (typically >10 À5 to 10 À4 of the assayed population). This lends itself well to the treatment and monitoring of diseases with a leukaemic phase, such as CLL (Thompson & Wierda, 2016) . However, for NHLs with predominantly nodal involvement, the circulating burden is typically too low to be detected by MFC, even at diagnosis. Even if present, lymphomatous CTCs in some cases, such as DLBCL, lack unique cell surface marker profiles, limiting the value of MFC. Therefore, more sensitive and specific techniques are needed to further MRD development in NHLs. Lymphoma cells are subject to destruction and necrosis, which may, in some cases, be immune-mediated (Jahr et al, 2001) . This results in the release of intracellular DNA into the local microenvironment as well as the peripheral circulation at quantifiable levels (Hohaus et al, 2009; Bohers et al, 2015) . The kinetics of clearance of this cell-free DNA (cfDNA) are not fully understood, but its half-life may be short, approaching 21 h (Lo et al, 1999) . Rapid clearance offers the ability to track quantitative changes in cfDNA and use it as a dynamic MRD measure (Leon et al, 1977) . Detection of circulating cfDNA utilizes polymerase chain reaction (PCR)-based technologies, and thus has excellent sensitivity (Narayan et al, 2012; Newman et al, 2014; Kurtz et al, 2015; Roschewski et al, 2015) . The specificity of the assay depends on multiple factors, related to the primers used and the variability in the targeted primer sequences. In fact, circulating tumour DNA (ctDNA) accounts for a minority of cfDNA in vivo; this presents a major hurdle in identifying low-level, tumour-specific targets from a background of cfDNA (Stroun et al, 2001) . Despite this, current techniques allow for the identification of ctDNA, by determining tumour-specific clonotypic target sequences from a tissue block (invasive tissue biopsy) or from peripheral blood (liquid biopsy) (Kurtz et al, 2015; Roschewski et al, 2015) . The former is currently of higher yield: identification of a unique clonotypic sequence may approach 100% when using tumour cell block with sufficient tumour DNA, as compared to identification rates ranging from 30% to 70% from peripheral blood (Roschewski et al, 2015) . However, more recent methods of clonotype identification in peripheral blood, described below, are reporting improved sensitivity without the use of a tumour tissue sample (Kurtz et al, 2015) . The limit of detection is assay-dependent but can be as low as 10 À6 (Kurtz et al, 2015) .
There are different types of tumour-specific targets that can be used for MRD, but they broadly segregate into disease-specific and patient-specific markers. Disease-specific methods rely on the presence of canonical abnormalities in certain lymphoma subtypes. For example, MCL and FL often harbour specific translocations that can be detected via PCR without the use of patient-specific primers (Bowman et al, 2004; Andersen et al, 2009; Pott et al, 2013) . However, this is not a universal feature of NHL; for example, DLBCL lacks a disease-defining chromosomal abnormality. Furthermore, even in MCL and FL, some patients lack the canonical translocations (Vega & Medeiros, 2003) . In those cases, patient-specific targets must be used. This can been done using real-time quantitative PCR (RQ-PCR), by first sequencing a patient's tumour, then building patient-specific primers for a region of interest (typically the rearranged immunoglobulin sequence), and using those in subsequent PCR analyses of peripheral blood samples (Andersen et al, 2002) . This method, referred to as allele-specific oligonucleotide (ASO)-PCR, has been fruitfully used for MRD determination in FL and MCL in patients lacking canonical translocations (Andersen et al, 2002; Kolstad et al, 2016) . However, one of its main limitations is the labour-intensive need to develop specific primers for each patient, which limits its broad applicability outside of specialized research settings.
The advent of NGS techniques has fostered the development of newer and more powerful methods for MRD monitoring using patient-specific targets. Those targets can be conceptually separated in 2 categories. First, one can capitalize on the fact that any lymphoid malignancy will have a unique immunoglobulin [Ig] (for B-cell malignancies) or Tcell receptor [TCR] (for T-cell malignancies) sequence, created through genetic rearrangements (Willis et al, 1997; Rambaldi et al, 2005; Zhang et al, 2010; Weng et al, 2013) . If the tumour Ig or TCR clonotype can be established, this sequence can then be used to identify and quantify ctDNA. We will refer henceforth to these methods as IgNGS approaches (TCR-based MRD detection is outside the scope of this review). Alternatively, one can look for somatic mutations or other genetic abnormalities that are present in a given patient's tumour and that can be used to track ctDNA (Newman et al, 2014; Simonsen et al, 2015; Scherer et al, 2016) . We will refer to these methods as mutNGS approaches. Both avenues are now possible using NGS-based methods . Below are brief descriptions of the NGS-based assays in current use or development, for which the salient characteristics are summarized in Table I .
The IgNGS method in most advanced development is the ClonoSeq â platform (Adaptive, Seattle, WA, USA) which has been already tested in a broad array of haematological malignancies (Spinelli et al, 2007; Putkonen et al, 2010; Logan et al, 2011; Armand et al, 2013; Kurtz et al, 2015; Roschewski et al, 2015) . This proprietary technology, and other similar research methods, uses a set of universal primers targeting all possible IGH VDJ rearrangements. A given patient's IGH VDJ clonotype can be identified by PCR and high-throughput sequencing analysis of tumour tissue (or peripheral blood if the circulating component is high enough); this clonotype can subsequently be quantified in a similar way from peripheral blood samples to measure MRD (Belzen et al, 1997; Logan et al, 2011; Gimenez et al, 2012; Carlotti et al, 2015) . This method was initially limited due to somatic mutations in targeted primer sequences, but now exhibits increased sensitivity thanks to improved primer design (Voena et al, 1997) . This allows the detection of ctDNA in most patients with DLBCL, MCL and FL, as described further below (Gimenez et al, 2012; Carlotti et al, 2015; Roschewski et al, 2016) . There are currently two mutNGS techniques in advanced development. The first is digital droplet PCR (ddPCR), which differs from traditional PCR methods in that it segregates individual nucleotide particles into distinct wells, typically in aqueous media (droplets), with the total number of individual droplet reactions in the tens of thousands (Hudecova, 2015; Alcaide et al, 2016) . Specific target primers are introduced into each well. The amplification of a single sequence can offer improved sensitivity and specificity for the detection of variants occurring at low circulating concentrations (Hudecova, 2015; Alcaide et al, 2016) . Currently, this technique is not as well developed as other NGS methods, but is able to identify ctDNA in solid and liquid malignancies Cavalli et al, 2017) . Concordance with more traditional sequencing of BCL2-IGH rearrangements has been demonstrated to be 82% in all samples and 98% in cases with quantifiable ctDNA levels (Cavalli et al, 2017) . Optimization of this technique for use with ctDNA Another mutNGS method is CAncer Personalized Profiling by deep Sequencing (CAPPseq), which is able to detect disease-specific mutations in cfDNA (Newman et al, 2014; Kurtz et al, 2016) . First validated in solid tumours, CAPPseq utilizes a disease-specific "selector", which is a set of exonic and intronic targets chosen to cover regions of known recurrent mutations for a particular cancer type. Those targets are then amplified and sequenced in a patient's blood sample, allowing quantification of tumour DNA based on the detection of tumour-specific mutations, and simultaneous determination of an individual's specific tumour mutation profile. This method can simultaneously assay for all important classes of mutations, including single nucleotide variants (SNV's), insertion/deletions (indels), copy number alterations and rearrangements. CAPPseq has allowed highly promising studies in both solid and haematological malignancies (Newman et al, 2014; Kurtz et al, 2016; Scherer et al, 2016) .
Based on their high sensitivity and ability to reliably identify patient-specific target sequences, mutNGS techniques have proven valuable in the characterization of novel mutations within already identified pathways of lymphomagenesis in DLBCL (Jiang et al, 2014; Bohers et al, 2015; Dubois et al, 2016) . Targeted sequencing of proteins known to be involved in B-cell signalling, toll-like receptor signalling, nuclear factor-jB, immunity, apoptoticand epigenetic regulation pathways can yield a library of novel SNV's which are readily detectable by CAPPseq in DLBCL (Jiang et al, 2014; Bohers et al, 2015; Kurtz et al, 2016; Scherer et al, 2016) .
The various NGS-based MRD techniques described above lend themselves well to multiple potential applications (Table II) . First, the quantitative level of ctDNA at initial presentation may have prognostic value for specific patient populations undergoing specific treatments, which could influence therapy choices (Hohaus et al, 2009; Galimberti et al, 2014) . Second, these techniques can monitor the clearance of ctDNA during frontline chemotherapy (Ladetto et al, 2006; Roschewski et al, 2015) . This interim monitoring offers a dynamic view of the early tumour response to therapy, which may allow modulation of treatment duration or intensity, or identify patients at high risk of therapy failure . Third, ctDNA measurement at end-of-treatment (EOT) could improve the ability to identify cured or optimally treated patients and, conversely, identify other patients who may benefit from continued or intensified therapy (Pott et al, 2010; Armand et al, 2013) . Fourth, after treatment has concluded, these technologies can be used for post-treatment surveillance (Galimberti et al, 2014; Kolstad et al, 2016) . This could serve a function similar to that of surveillance imaging Table II but without radiation exposure and, potentially, with an increased degree of sensitivity for pre-clinical relapse, allowing eventually the testing of pre-emptive interventions. Finally, serial sampling can also allow for monitoring of clonal patterns of evolution, which may have important prognostic and therapeutic implications (Jiang et al, 2014; Bohers et al, 2015; Carlotti et al, 2015) . In the following sections, we summarize the existing data and possible uses of these nextgeneration MRD assays in DLBCL, MCL and FL along those five lines.
Diffuse large B cell lymphoma
Diffuse large B cell lymphoma is an aggressive tumour that is curable in a majority of patients. Most commonly, frontline therapy relies on a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or similar multiagent chemoimmunotherapy regimens (Coiffier et al, 2002) . While robust clinical and molecular risk stratification systems exist, they are only rarely used to modify the choice of treatment. DLBCL has historically not lent itself to MRD analysis because the circulating tumour burden is low and the immunophenotype is often similar to that of normal B cells. However, next-generation methods have yielded very promising results. Indeed, DLBCL ctDNA is readily detectable at diagnosis using either IgNGS or mutNGS techniques (Willis et al, 1997; Armand et al, 2013; Kurtz et al, 2015; Roschewski et al, 2015) .
Already, MRD measurements using NGS methods in DLBCL are showing potential clinical relevance. First, they can be used to refine prognosis at the time of diagnosis. Indeed, both IgNGS and mutNGS studies have suggested that increasing levels of ctDNA levels at diagnosis have a significant negative impact on outcomes (Hohaus et al, 2009; Zohren et al, 2015) . Quantitative cut-off levels at presentation vary between studies, making it harder still to compare results across studies. One study of patients with DLBCL used a cut-off of 0Á29 ng/dl at presentation and found that only 40% of those with "high levels" of ctDNA versus 88% of those with "low levels" of ctDNA had freedom from treatment failure at 24 months (Hohaus et al, 2009 ). This information could be used as a rationale to investigate the selective use of more aggressive regimens in patients with high level ctDNA at diagnosis.
Moreover, monitoring of interim samples has shown that MRD status after Cycle 2 has significant impact on time to progression at 5 years [for example, 80% in MRD negative and 41% in MRD positive patients using IgNGS in one study (Roschewski et al, 2015) ]. Similarly, a study using CAPPseq showed that the rapidity of clearance assessed as early as Cycle 2 of R-CHOP could reliably predict attainment of complete remission . On-treatment MRD evaluation may also provide early prediction of outcome for patients undergoing non-curative therapy for relapsed/refractory disease .
Minimal residual disease measurements may also be useful at EOT for patients in radiographic complete remission. Some of those patients continue to harbour molecular disease, presumably heralding future clinical relapse (Roschewski et al, 2015) . Both IgNGS and mutNGS have been able to identify molecularly persistent disease at EOT . In one study, patients with persistent molecular disease, as detected by clonotypic IGH-VDJ rearrangements, had significantly worse PFS (3Á8 months) compared to those with molecular remission followed by molecular recurrence (5Á8 months) (Roschewski et al, 2015) . Of course, it is still unknown whether intervention through maintenance therapy or salvage would change outcomes in those with MRD positivity, but NGS MRD techniques at least afford the ability to test this possibility through clinical trials. Ideally, early intervention would be able to limit the toxicity and cost of salvage therapy, especially if it can eliminate the need for stem cell transplantation. Another possibility would be to use a high-intensity therapy, such as autologous stem cell transplant (ASCT) for patients with MRD positivity at EOT. The use of ASCT for consolidation of first remission has been the subject of many studies, most showing no significant improvement in OS (Farooq & Laport, 2015) . However, this lack of demonstrated benefit could reflect the high cure rate achievable with R-CHOP alone; the results could be different if the procedure were reserved for the high-risk subset of patients with MRD positivity at EOT. At present, most patients who undergo ASCT for DLBCL do so for chemo-sensitive relapsed/refractory disease. In this context, the goal of ASCT is cure, although many patients still relapse. One of the reasons may be the reinfusion of a contaminated stem cell product (Herrera et al, 2015) . It is possible to test for the presence of MRD in the product itself, and a preliminary study suggested that MRD positivity of the product portends a poor transplant outcome (Herrera et al, 2015) . If this is confirmed, this could allow patients with contaminated products to be treated with an alternative treatment strategy or an intensified post-ASCT treatment.
Patients with DLBCL who attain complete remission are currently followed with clinical surveillance, with or without radiographic surveillance. However, relapse in aggressive lymphoma is often acute and unpredictable, occurring so rapidly that it is not always detectable radiologically before clinical relapse. As such, the value of surveillance with CT or PET has repeatedly been called into question, as these methods have not been shown to impact patient outcomes (Thompson et al, 2014; Huntington et al, 2015) . Ideal surveillance methods would have a high sensitivity and an ability to increase lead time, allowing for intervention before clinical relapse. Surveillance monitoring utilizing both IgNGS and mutNGS may be of sufficient sensitivity to be utilized in this way. Several studies have shown that persistent MRD negativity in surveillance is highly predictive of continued remission (Kurtz et al, 2015; Roschewski et al, 2015) . Conversely, nearly all patients who remain in remission maintain MRD negativity, with one study finding 88 of 90 remaining MRD negative using IgNGS (while the other two transiently became MRD positive with later clearance) (Roschewski et al, 2015) .
The clinical applicability of these data depends on two assumptions. First, molecular relapse must precede clinical relapse by a period of time long enough to allow for intervention; second, the pre-emptive intervention allowed by this lead time must impact outcome. Several studies have shown that the detection of molecular relapse by NGS may precede clinical relapse by several months, although more robust prospective data are still needed (Kurtz et al, 2015; Roschewski et al, 2015) . The ability to detect molecular relapse before clinically evident disease would probably be improved with increased frequency of blood sampling; the existing studies evaluated patients at six-month intervals, which could hamper the early detection of relapse if the average lead-time is closer to 3 months. Naturally, this has to be balanced with the cost of the test, since every 3-month monitoring for several years for all patients, knowing that only a minority will eventually relapse, will accrue significant financial cost per relapse anticipated. Perhaps even more importantly, active surveillance while in clinical remission may offer opportunity for early intervention, but it remains to be proven that pre-emptive intervention for pre-clinical relapse will improve outcomes, and no data to support this hypothesis exist at present. Possible strategies may include a maintenance strategy, such as lenalidomide or immunotherapy-based intervention, but dedicated prospective and wellcontrolled studies will be needed to validate this concept (Ansell et al, 2009; Ferreri et al, 2017) .
The final applicability of MRD in DLBCL is to detect the appearance of new clones, representing evolutionary adaptation in the setting of stress (Jiang et al, 2014; Roschewski et al, 2015) . Cytotoxic treatment may select for divergent populations, some with novel mutations causing dysregulation of pro-apoptotic and anti-proliferative pathways (Alizadeh et al, 2000) . With the increasing use of targeted therapies, and the growing understanding of molecular mechanisms of resistance it could be critical to know early about the appearance of new mutations that could justify a change in therapy or at least closer monitoring for progression, as has been suggested in CLL under Bruton tyrosine kinase (BTK) inhibition (Woyach, 2017) . In this context, IgNGS is not as useful as mutNGS. IgNGS does have the potential to track different clones with different IGH VDJ rearrangements, provided that the clones were present in the original tumour sample; but this is not likely to inform the development of treatment resistance. In contrast, mutNGS lends itself well to this goal, as it specifically seeks mutations that are known to be important in a given disease type (Jiang et al, 2014; Imamura et al, 2016; Roschewski et al, 2016) . Ultimately, it seems plausible that high-throughput analysis will further open the door for personalized medicine and dynamic selection of therapy in individual patients.
Mantle cell lymphoma
Mantle cell lymphoma is not currently a curable disease (at least without allogeneic stem cell transplantation). While recent advances in the frontline management of MCL have resulted in significant gains, with an expected median PFS now in excess of 5 years, compared to median OS less than 5 years a decade ago, most patients will succumb from their disease within 10 years of diagnosis (Inamdar et al, 2016) . In addition, the frontline regimens associated with the longest PFS incorporate aggressive multi-agent chemotherapy and ASCT, which incurs significant morbidity and occasional mortality. Yet MCL remains a heterogeneous disease, which is only incompletely captured by current clinical and pathological risk stratification tools. It would therefore be clinically useful if MRD techniques could allow modulation of treatment duration and intensity in this disease.
Classical MCL expresses the 11:14(q13;q32) translocation which results in a CCND1-IGH fusion gene (Zelenetz et al, 2010) . This unique target is often detectable via PCR in the plasma of patients with MCL and can be detected with consensus primers or through nested PCR (Andersen et al, 2009; Pott et al, 2013) . However, a significant subset of patients with MCL do not possess the translocation (Vega & Medeiros, 2003) . The detection of ctDNA in those patients must rely on other clonotypic sequences. Unique IGH-VDJ rearrangements have been most commonly targeted with comparable success to DLBCL (Belzen et al, 1997; Gimenez et al, 2012; Liu et al, 2012) . Unlike most testing in DLBCL, the methods employed in many large MCL studies have relied on ASO-PCR. This method utilizes consensus primers to sequence the patient's Ig rearrangement, in order to develop patient-specific IGH primers that are then utilized in subsequent PCR analyses (Andersen et al, 2002 (Andersen et al, , 2009 Kolstad et al, 2016) . This technique has a sensitivity similar to other PCR-based techniques, with a reported ability to detect 1 tumour cell out of 10 5 cells (Andersen et al, 2002) .
ClonoSEQ â , which provides a more direct way to establish and track the tumour clonotype, has also been used in MCL (Faham et al, 2012; Armand et al, 2016) . Alternatively, using PCR targeting a single gene can track common mutations. As proof of concept, SOX11, the gene encoding a transcription factor involved in cellular differentiation, has been shown to be upregulated in the majority of patients with MCL and displays similar kinetics to other MRD markers (Simonsen et al, 2015) . Minimal residual disease in MCL, as in DLBCL, can be applied in several ways. For example, it is possible to use MRD assessments to investigate whether quantitative levels of ctDNA have prognostic implication at end of induction for patients in remission. In one such study, MRD positivity at EOT did indeed independently confer a worse PFS at 2 years (Pott et al, 2010) . Conversely, MRD negativity at EOT has been shown to predict long disease-free survival (Andersen et al, 2009; Liu et al, 2012) . This has been observed with a Review number of different MRD techniques including IGH-CCND1, IGH VDJ, or SOX11 tracking (Andersen et al, 2009; Pott et al, 2010; Simonsen et al, 2015) . In one study, patients in complete remission after R-CHOP or hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine) induction therapy were assessed for MRD status before ASCT. Those harbouring persistent pre-transplant MRD had a significant reduction in PFS and OS (median 3Á0 and 2Á3 years respectively compared to those without MRD (median not reached with 82% PFS and 75% OS at 5 years) (Cowan et al, 2016) . This raises the possibility that EOT MRD could be used to guide the decision of whether or not to proceed to ASCT, specifically whether MRD negative patients at end-of-induction could be treated instead with maintenance therapy. This would have enormous implication for patients, if it affords many the ability to avoid the risk and cost of ASCT.
While ASCT improves PFS and can induce molecular remission in patients with pre-transplant MRD positivity, the expectation is still that all patients will eventually relapse (Kolstad et al, 2016) . Surveillance monitoring with MRD offers the opportunity to initiate therapy prior to overt relapse, which has been attempted with rituximab (Ladetto et al, 2006; Andersen et al, 2009; Cowan et al, 2016; Kolstad et al, 2016) . Indeed, several studies have shown rituximab to be effective in re-inducing molecular remission after ASCT in 80-100% of cases (Brugger et al, 2004; Ladetto et al, 2006; Andersen et al, 2009; Kolstad et al, 2016) . Furthermore, a recently presented randomized trial showed that rituximab maintenance after ASCT improved PFS and OS (Le Gouill et al, 2016) . Because rituximab is costly and associated with possible adverse effects, such as cytopenias, infection and hypogammaglobulinaemia, the ability to target at-risk patients would be worthwhile, and may be provided by MRD measurements. Already the results of MRD-driven maintenance rituximab by the Nordic Lymphoma Group are encouraging in this regard and suggest, albeit in a non-randomized fashion, that the detection of molecular relapse may allow useful early deployment of rituximab maintenance therapy (Kolstad et al, 2016) . In this study, patients had, on average, a 55-month interval from molecular relapse to clinical relapse when treated pre-emptively with maintenance rituximab (Kolstad et al, 2016) . Most of these patients (87%) did achieve MRD negativity but nonetheless suffered a second molecular relapse (69%), indicating that the benefit of rituximab in this setting may be primarily to stave off relapse for a few years.
Finally, there are several targeted agents in use or in development for MCL, including the BTK inhibitor, ibrutinib, and the BCL2 inhibitor, venetoclax. Those drugs appear to be very active in relapsed/refractory disease but are currently given continuously until treatment failure, again with significant cost and potential toxicity (Wang et al, 2015; Tam et al, 2016) . This provides another possible use of MRD, to potentially allow treatment interruption in MRD-negative responders.
Follicular lymphoma
Follicular lymphoma (FL), while also incurable with conventional therapy, is more indolent than DLBCL and MCL. Given this protracted course, there is a dearth of high-quality, prospective studies on MRD that report long-term follow-up. Most current investigations have utilized the diseasedefining translocation t(14;18)(q32;q21) which results in the juxtaposition of the BCL2 gene to the IGH enhancer sequence (Zelenetz et al, 2010) . This translocation is felt to an important driver of lymphomagenesis, but can occur in various portions of the major breakpoint, 3 0 -major breakpoint, minor cluster and 5 0 -minor cluster regions, and its detection requires the use of nested PCR for improved sensitivity. The ability to track MRD using this translocation alone seems to be lower than that in MCL, perhaps limited to fewer than half of patients (Goff et al, 2009; Scholz et al, 2013; Galimberti et al, 2014) . Identification of a clonotypic IGH VDJ sequence is needed for MRD monitoring in the remainder of patients. The use of co-testing for t14:18 and IGH VDJ rearrangement by ASO-PCR can identify a targetable sequence upwards of 90% of the time (Ladetto et al, 2002; Pott et al, 2016) . Utilization of ClonoSEQ â or CAPPseq methods could potentially capture a similarly high or higher number of MRD-evaluable patients, but data are lacking at present. Pre-treatment levels of ctDNA in FL not only correlate with high-risk features used in the FL international prognostic index (FLIPI), but are independently predictive of treatment failure (Zohren et al, 2015; Sarkozy et al, 2017) . Elevated ctDNA levels have been shown to portend shortened PFS in patients with intermediate and high risk FLIPI scores (Rambaldi et al, 2005; Ladetto et al, 2013) . This may not be applicable across all treatment regimens, as patients treated with 90 Yttrium-Ibritumomab-Tiuxetan did not have a significant correlation between peripheral blood levels of ctDNA and PFS. This highlights the important caveat that results obtained with a given MRD method may have different clinical implications depending on the therapy used (Goff et al, 2009) .
The natural course of FL is not linear and typically involves prolonged periods of progression-free disease, even in the absence of treatment. Not surprisingly, therefore, the kinetics of MRD clearance have been variable (van Oers et al, 2010; Zohren et al, 2015) . Multiple chemotherapeutic regimens in combination with anti-CD20 monoclonal antibodies have been shown to be effective in inducing molecular remission, but the implications of this data are mixed, although there is suggestion that sustained molecular remission after chemotherapy most likely predicts improved PFS (Scholz et al, 2013; Zohren et al, 2015; Barta et al, 2016) . In this setting, it is not clear that MRD would bring significant value, given that all patients are expected to eventually relapse after chemoimmunotherapy, and there is no obvious value to the early detection of such relapse. In fact, it has been a dogma in FL that early treatment does not influence outcome; if this remains true for pre-clinical relapse, the value of its detection may be limited.
Yet MRD may be useful in some treatment settings. Some patients with FL undergo treatment with chemotherapy followed by ASCT. This regimen is usually reserved for patients with relapsed/refractory disease, given that its use as first line therapy has not been shown to increase OS, unlike in relapsed or refractory disease (Schouten et al, 2000; Al Khabori et al, 2012; Arcaini et al, 2015) . While no data exist at present, the rigorous testing of MRD in the pre-ASCT setting and even in the stem cell product (as in DLBCL) could potentially allow the optimal targeting of ASCT to patients most likely to benefit. Furthermore, patients in molecular remission after ASCT have been repeatedly shown to have improved PFS compared to those with retained MRD positivity (Ladetto et al, 2002; Morschhauser et al, 2012) . Those who fail to attain full molecular remission could potentially be treated with rituximab maintenance (Brugger et al, 2004; Pulsoni et al, 2016) . Patients receiving rituximab due to MRD positivity post-transplant appear to have improved PFS compared to matched historical controls in the pre-rituximab era (Pulsoni et al, 2016) . With the development of more effective CD20-directed antibodies, such as obinutuzumab, the benefit of MRD-targeted maintenance therapy could be even greater.
Interestingly, serial surveillance sampling after treatment of FL clearly shows vertical and divergent evolutionary patterns of the disease (Weigert et al, 2012; Carlotti et al, 2015) . As such, FL can be oligoclonal (Carlotti et al, 2015) . Future research, especially using mutNGS, could serve many useful purposes, as in DLBCL, including (i) refining our dynamic risk-stratification ability based on the emergence of new mutations; (ii) early termination or intensification of treatment in patients with the emergence of mutations predicting resistance; and (iii) interruption of continuous treatment with targeted agents (e.g., with idelalisib) in patients who become MRD negative on treatment (Eyre et al, 2017) .
Conclusions
There has been tremendous progress in the field of lymphoma in the last few years, with a growing and deepening understanding of lymphoma pathology, clinical and molecular risk factors, and a rapidly expanding arsenal of chemotherapy, tumour-targeting monoclonal antibodies, small molecule pathway inhibitors and immunotherapy. Yet our ability to optimally match treatment to patient, and to do so dynamically through the course of therapy, is still embryonic. NGS-based MRD tools, such as the ones described above and their refinements undoubtedly to come, have the potential to revolutionize treatment paradigms across all lymphoma histologies. They may be used to help select frontline therapy, but more likely will be instrumental in adapting therapy to response, whether it be with change in treatment, intensification or de-escalation of treatment, or use of maintenance therapies. Recent data suggest they may be able to guide interventions after allogeneic stem cell transplantation as well (Herrera et al, 2016) . In addition, they will probably allow a new generation of clinical trials to be performed based on early detection of relapse and pre-emptive intervention.
The full realization of the potential benefit of MRD in lymphoma care has several important obstacles. One is the lack of incorporation of MRD monitoring in prospective trials evaluating novel treatment strategies. Many ongoing clinical trials in lymphoma do not track MRD as an endpoint. Some of the MRD tools are proprietary and their inclusion in a clinical trial significantly adds to its cost. The publication of non-proprietary methods, such as CAPPseq, provide an important tool for researchers, but requires significant infrastructure investment and technical expertise. Whether proprietary or not, while high-throughput sequencing will probably continue to increase in availability and affordability, the per-sample cost remains high, and will need to decrease to allow widespread and repeated use. At present, no data exists that evaluates the overall healthcare expenses associated with these techniques or the impact on patient quality of life. Furthermore, intervention MRD-based trials, especially in more indolent diseases, such as FL and MCL, have long delays until the read-out of the most important outcomes, such as OS. This creates a paradox where the pace of technical evolution outstrips the time needed for study enrolment, intervention, data analysis and interpretation. In addition, interpretation of MRD-based trial data requires particular care, given the dynamic nature of MRD events. While this topic falls outside the scope of this review, the potential statistical complexity of MRD analyses should not be overlooked. Finally, as MRD techniques allow the detection and tracking of different tumour clones, we will need to dissect the pathological meaning of those changes before we can optimally intervene on the basis of their detection.
Despite these obstacles, the power of NGS-based MRD testing, even based only on preliminary data, seems too broad and too large to fail. We therefore hope that MRD testing is incorporated in a large number of clinical trials, initially to best understand its implications, and subsequently to drive treatment decisions. This may soon bring us closer to the goal of individualized and dynamically optimized patient care.
